Praxis Precision Medicines Shares Phase 2/3 POWER1 Study Findings

Praxis Precision Medicines (NASDAQ:PRAX) announced the results of its Phase 2/3 POWER1 study evaluating vormatrigine for focal onset seizures. While primary endpoints were not met, positive efficacy signals in higher dose groups and a strong safety profile were observed.

By Muhammad Ali Khalid Fri, June 5, 2026 at 6:55 PM GMT+3 2 min read · Yahoo Finance · June 5, 2026, 15:55 UTC

Praxis Precision Medicines Shares Phase 2/3 POWER1 Study Findings

Tickers: $PRAX

Topics: drug_development epilepsy neurology

Read the full article at Yahoo Finance

More World news

Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC